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and Michael Borre2†Abstract
Background: Prostate cancer is one of the leading causes of cancer death amongst men in economically advanced
countries. The disease is characterized by a greatly varying clinical course, where some patients harbor non- or
slowly-progressive disease, others highly aggressive disease. There is a great lack of markers to differentiate between
aggressive and indolent disease. Markers that could help to identify patients needing curative treatment while sparing
those who do not.
Methods: MicroRNA profiling of 672 microRNAs using multiplex RT-qPCR was performed using 36 prostate cancer
samples to evaluate the association of microRNAs and biochemical recurrence after radical prostatectomy.
Results: Among 31 microRNAs associated with recurrence, we identified miR-449b, which was further validated in an
independent cohort of 163 radical prostatectomy patients. Patients expressing miR-449b had a significantly higher risk
of recurrence (HR = 1.57; p = 0.028), and miR-449b was shown to be an independent predictor of recurrence after
prostatectomy (HR = 1.9; p = 0.003) when modeled with known risk factors of recurrent disease in multivariate
analysis.
Conclusion: High miR-449b expression was shown to be an independent predictor of biochemical recurrence
after radical prostatectomy.
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There is a great unmet need for better diagnostic as
well as predictive tools in prostate cancer (PC) needed
for discerning aggressive PC from indolent PC. Al-
though this disease has the second highest cancer mor-
tality amongst men, approximately 250,000 worldwide
[1]. The prevalence hereof, as indicated by autopsy
studies, is even higher and reported as being up to 12-
54% of all men aged over 50 years [2]. Early diagnosis is
imperative since curative treatment is only possible in
non-metastatic PC. This has led to the widespread use
of screening for PC using Prostate Specific antigen* Correspondence: lars@clin.au.dk
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article, unless otherwise stated.(PSA) testing, but since the prevalence of non-lethal,
non-progressive PC is very high, screening leads to a
substantial risk of overtreatment [3]. Biomarkers associ-
ated with aggressive PC have the potential of improving
existing prediction models for identifying patients with
aggressive disease and thus aid patients and physicians
in deciding between curative treatment and active sur-
veillance [4]. Furthermore, biomarkers associated with
aggressive disease could be used for monitoring patients
in active surveillance and be used as a trigger for offering
curative treatment if the biomarker level changes [5].
In brief, microRNAs are small 18 to 25 nucleotide
RNA molecules that function as regulators of gene ex-
pression through incorporation into the RNA-induced
silencing complex (RISC). The incorporated microRNA
binds to mRNA sequences with complementary to the
microRNA. Following binding, the Argonaute (Ago)tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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strand and thus causes degradation of the target tran-
script and thereby silences the gene [6]. Through this
post transcriptional process miRNA can influence gene
expression and thus regulate various biological pro-
cesses. Since the key biological differences between can-
cer cells and their normal counterparts are the initiation
and utilization of cellular processes like increased prolif-
eration, immortalization and invasive properties, altering
gene expression is central in tumorigenesis [7]. Previous
studies have shown that miRNA can be central in or-
chestrating the altered gene expression necessary for the
cell to undergo transformation to a cancer cell [6]. As
each miRNA can have many different putative target
mRNAs, a miRNA can essentially be the central tumori-
genic factor [8] or it can function through inhibiting
mRNAs that in turn function as either oncogenes or
tumor suppressors [9,10].
miRNAs are generally more stable and easier to meas-
ure in biological material where degradation is an issue
compared to mRNA [11,12]. Therefore, miRNAs may
prove to be good biomarkers for diagnosis as well as for
monitoring PC. It has been shown in several studies that
miRNA can be assayed in blood from PC patients and
that diagnostic miRNAs can be identified [13,14].
Several studies have shown that miRNAs are aber-
rantly expressed in PC and several specific miRNAs have
been implicated in PC development [15-19]. While most
studies of miRNA in PC have focused on miRNAs differ-
entially expressed between normal and cancerous pros-
tate tissue, only a few studies have focused on miRNA
expression associated with aggressive disease. A number
of different surrogate end-points for aggressive PC have
been used in the studies like presence of perineural inva-
sion [20], Gleason grade [20,21], extra prostatic growth
[16] and risk of recurrence [22]. These differences in
end-points, and the limited power of some studies due
to few analyzed samples, are probably the main rea-
sons that reproducing results is difficult, as described by
Coppola et al. [23].
Here we performed microRNA profiling using multi-
plex qPCR on laser micro dissected material from 36 PC
patients to identify microRNAs associated with recur-
rence after radical prostatectomy (RP). We validated the
association with recurrence of the top ranked miR-449b




The study was approved by the Central Denmark Region
Committees on Biomedical Research Ethics case number
2002-41-2640. Informed written consent was obtained
from all patients.Clinical samples
Samples for this study were provided by the Aarhus
prostate cancer project consisting of all patients under-
going radical prostatectomy at the Dept. of Urology
Aarhus University Hospital from 1995 to present day.
Samples included in the study were from 2003 to 2007.
Clinical data were collected prospectively and recur-
rence status for all patients in the study was updated
prior to inclusion in the study. The prostatectomy spec-
imens were examined by an experienced uro-genito-
pathologist assessing pathological stage (pT) and tumor
differentiation scored according to Gleason. No re-review
of the Gleason grade was performed. Serum PSA was
measured prior to surgery by automated immunoassay
using DPC Total PSA Immulite and expressed in ng/mL.
Clinical follow up after surgery was conducted by PSA
measurements at 3, 6, and 12 months postoperatively
and thereafter biannually. Subsequent biochemical fail-
ure was defined as two consecutive measurements of
PSA > 0.2 ng/mL. Needle biopsies were taken from the
surgical prostatectomy specimen and immediately snap
frozen.
For the validation phase, samples cores 1.5 mm in
diameter were taken from formalin fixed paraffin em-
bedded (FFPE) radical prostatectomy specimens. The pa-
tient cohort [24,25] and sampling protocol for RNA
extraction have previously been described. All clinical in-
formation from the patient cohort was updated regard-
ing recurrence status prior to inclusion in the current
study. Patients with at least 4 years recurrence free sur-
vival and patients with proven biochemical recurrence
were included.
Laser micro dissection and RNA extraction
Survey slides of the biopsies were examined and the
carcinoma cells identified. Since all material was reeval-
uated by an experienced uro-genito-pathologist to en-
sure that only tumor tissue was included. Subsequently,
slides were stained with cresyl-violet 1% and the carcin-
oma cells were laser micro dissected using the PALM
laser microbeam system. RNA extraction was performed
using RNeasy® Micro kit from Qiagen (Germany). Flow
through from the RNA extraction contains RNA frag-
ments that are shorter than 120 nucleotides in length, thus
the total microRNA fraction was contained within the
flow through. A second microRNA extraction was per-
formed on the flow through with RNeasy micro kit opti-
mized for extracting micro RNAs.
RNA extraction from FFPE tissue was performed
using RNeasy® FFPE Kit (Qiagen Germany) in which
the total RNA fraction contains RNA fragments down
to 18 nucleotides in length. RNA260/280 ratio and the
RNA concentration of each sample was measured using
NanoDrop (Tecan).
Table 1 Clinical and histopathological characteristics of





Total number of cancer samples 36 163
Age median(range) Years 63 (46–71) 62(48–72)
Gleason grade
Low (5–6) 17 (47%) 60 (37%)
Intermediate (7) 15 (42%) 85 (52%)
High (8–10) 4 (11%) 18 (11%)
Pathological stage
T2a-c 19 (53%) 96 (59%)
T3a-b 17 (47%) 67 (41%)
Time to recurrence (range) Months 15.6 (1–74) 24 (3–122)
Follow up non-recurrent cases Months 66 (31–80) 65 (48–114)
Recurrence
Yes 22 (61%) 96 (59%)
No 14 (39%) 67 (41%)
Margin status
Positive 16 (44%) 45 (28%)
Negative 20 (56%) 118 (72%)
Pre-operative PSA (range) 16.0 (5.3-42.5) 13.2 (2.1-64.5)
FF: fresh frozen tumors. FFPE: formalin fixed paraffin embedded tumors.
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miRNA expression profiling was carried out using Taq-
man Low Density Array Human microRNA A + B Cards
v3.0 (Micro fluid cards, Applied Biosystems, Foster City,
USA). Equal volumes of flow-through were used as input
material, and the miRNA was reverse transcribed using
Megaplextm pool A and B (Applied Biosystems) followed
by pre amplification. The cDNA pool was applied to the
multiplex array cards and the experiment was run on
the ABI 7900 HT platform using cycling conditions as
provided by the manufacturer. Normalization of results
was done using RQ Manager (Applied Biosystems). A
common threshold was established across all array cards
for each miRNA, expression levels were normalized to
MammU6 and average delta-Ct was used in downstream
analyses. miRNA expression data is available at GEO
(NCBI) with series accession no. GSE62610.
A total of 350 ng total RNA was reverse transcribed
using Megaplextm pool A (Applied Biosystems) followed
by pre-amplification according to manufacturer protocol
for miRNA expression profiling in FFPE tissue. We per-
formed singleplex RT-PCR amplifications for each of the
candidate miRNAs selected for validation using Taq-man
probes with the assay ids: 001129, 002255, 002306,
002295, 001608 and 001960, with MammU6 as reference.
All samples were measured in triplicates and a no tem-
plate and a no RT control were included on all plates.
Statistical analyses
Statistical analyses were performed using STATA version
10.1 (StataCorp, College Station TX, USA). P-values <
0.05 were considered statistically significant. Ranking of
the miRNAs was done using Mann–Whitney rank-sum
test in the screening study. Median fold change was
given by the relation between the median expression
level in the recurrent group versus the level in the non-
recurrent group. Association with biochemical recur-
rence after radical prostatectomy was analyzed using
univariate and multivariate Cox regression analysis in
the validation study. For each variable in the Cox regres-
sion analyses the proportional hazard assumption was
verified by log-log survival curves. The prediction accur-
acy was estimated using Harrell c’s concordance index.
Pathological T-stage was dichotomized in localized and
extra prostatic disease. Gleason score was grouped in
three categories containing scores 5–6, 7, and 8–10 re-
spectively. Preoperative PSA levels were grouped accord-
ing to the D’Amico classification with <10 ng/ml, 10 to
20 ng/ml and >20 ng/ml.
Results
In total, 36 tumor samples were laser micro dissected
and 672 miRNAs profiled using multiplex RT-qPCR to
identify novel miRNAs associated with recurrence afterRP. Sixty % of the patients had suffered recurrence and
the median follow-up of those without recurrence was
66 months (range 31–80 months). Clinical and histo-
pathological information is listed in Table 1. Initially the
miRNA expression data was filtered to exclude miRNAs
with no detection above background in any of the sam-
ples, leaving 536 miRNAs for further analysis. A total of
235 (44%) miRNAs were detected in all samples in the
filtered dataset.Delineation of key miRNA transcripts associated with
outcome
We delineated miRNAs that showed significant associ-
ation with recurrence. In total, 28 miRNAs were found
to be significantly up regulated and 3 miRNAs were sig-
nificantly down regulated in tumors from patients with
recurrence (p < 0.05 Mann–Whitney), compared to tu-
mors from patients without recurrence. Median fold
changes between recurrent and non-recurrent cases
ranged from 1.18 to 16 in the up regulated miRNAs and
4.2 for the down regulated miR-24-1-5p (Table 2). Top
ranked up regulated miRNA was miR-449b (p = 0.0061,
Mann–Whitney) with a 2.8 times higher expression in
patients with recurrent disease compared with patients
with non-recurrent disease.







Up regulated in recurrent cases
mir449b 0.0061 [16,22] 2.80 X










mir484 0.0252 [16] 1.71
mir126 0.0252 [20] 2.34
mir223 0.0297 2.01 X
mir636 0.0297 2.23






mir214 0.0442 2.10 X




mir10a 0.0478 [20] 2.06
mir10b 0.0478 [20,22] 1.94
Down regulated in recurrent cases
mir24-1* 0.0298 3.43
mir154 0.0353 [19] na.
mir873 0.0406 na.
Table 3 miR-449b expression in relation to the clinical
variables in the validation cohort






Total number of cancer samples 78 85
Gleason grade 0.27
Low (5–6) 27 33
Intermediate (7) 45 40





0-10 ng/ml 22 27
10-20 ng/ml 44 31
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No miRNAs were significantly associated with recur-
rence when using conservative Bonferroni correction for
multiple testing corrections – likely due to the small ini-
tial patient cohort. To compensate for this we performed
an independent validation of the most significant miR-
NAs. Initially we selected a subset of 40 patients (20 re-
current and 20 non-recurrent patients) to investigate
candidate miRNAs before testing the miRNAs using the
whole cohort. Criteria for selecting miRNAs for valid-
ation were the p-value in rank-sum test, fold change,biological function determined in the literature, and fi-
nally for technical reasons that the assay was included in
the Megaplex pool A used for cDNA synthesis and pre-
amplification. Based on these criteria, six miRNAs were
selected for validation: miR-449b, miR-137, miR-149,
miR-214, miR-223 and miR-615-3p. We found miR-449b
expression to be associated with recurrence status in the
40 patients (p = 0.017, Chi2-test). MiR-137 and miR-615-
3p failed qPCR amplification, and there were no signifi-
cant association between expression level of the miRNA
and recurrence status for the rest (data not shown).
Consequently, only miR-449b was measured in the en-
tire validation cohort.
The entire validation cohort consisted of RNA sam-
ples extracted from FFPE tissue samples originating
from 163 patients who underwent radical prostatec-
tomy. Clinical characteristics of the validation cohort
are summarized in Table 1. Of the 163 samples, 78 (48%)
of the samples had detectable miR-449b expression above
background. We found a significant association between
miR-449b expression and PSA group (p = 0.02; chi2), but
no association with other clinical variables as shown in
Table 3. Using univariate Cox regression analysis, we
found that expression of miR-449b was significantly asso-
ciated with the risk of recurrence after RP (HR = 1.57,
p = 0.027). This correlation was also observed from
Kaplan-Meyer survival estimates (Figure 1). In multivariate
Figure 1 Kaplan-Meier survival curves showing recurrence free survival as function of miR-449b expression in the validation cohort.
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pathological t-stage, margin status, age and preopera-
tive PSA, we found that miR-449b expression was an
independent predictor of recurrence after RP (HR =
1.90, p = 0.003) (Table 4). The overall prediction accur-
acy determined by the Harrell´s C index of the multi-
variate model containing clinical variables alone was
0.69, compared to 0.71 when miR-449b expression
status was added to the model.
Discussion
Our study revealed 31 miRNAs differentially expressed
between patients suffering recurrence and patients
with no recurrence. Furthermore the top ranked miR-
449b was successfully validated in an independent co-
hort of 163 patients using RT-qPCR and found to be
an independent predictor of biochemical recurrence
after prostatectomy.
miRNA in relation to cancer constitutes an interesting
field of research due to their role in gene expression
regulation and because they are generally more stable
than mRNA. There is however a number of conflicting
results from miRNA profiling studies including irrepro-
ducible results. One major issue is the sample itself, andTable 4 Univariate- and multivariate analysis of recurrence fr
Univariate
HR (95% confidence interval)
miR-449b expression 1.57 (1.05-2.37)
Organ confined 2.76 (1.83-4.16)
Gleason grade 1.64 (1.21-2.23)
PSA 1.88 (1.41-2.50)
Margin status 1.14 (1.02-1.28)
Age 1.01 (0.97-1.05)
Clinical model
Clinical model with miR-449b expression
Values in bold indicate significant uni- and multivariate analysis (P<0.05).the tissue actually being profiled. Samples where the
carcinoma cell percentage is low, will inevitably reveal a
miRNA profile which is a mix the miRNAs from the
carcinoma cells and the profile from the surrounding
normal tissue, thus diluting the miRNA expression in
the carcinoma cells. Regarding studies of aggressive PC,
tumor heterogeneity has often been overlooked. Normally
only a single tumor biopsy is used and the miRNA profile
produced is a measurement of the miRNA expression in
that given part of the tumor. If the tumor contains more
aggressive clones in other parts of the prostate a dis-
crepancy will arise between the clinical performance of
the tumor and the miRNA profile obtained from the
more indolent tumor cells. Another issue influencing
reproducibility is the technical differences between
studies. Although good reproducibility exist within RT-
qPCR profiling platforms, the correlation with micro-
array platforms is often not high, as reported by Chen
et al. [26]. The number of miRNAs actually being pro-
filed also differs between studies ranging from 119 [19]
to 676 [22], in addition since different platforms are
used the specificity and sensitivity of the probes detect-
ing the miRNAs can differ leading to greater variability
of the expression measurements. However, in spite ofee survival in the validation cohort
Multivariate
p-value PA % HR (95% confidence interval) p-value PA %
0.028 0.55 1.90 (1.25-2.85) 0.003
<0.001 0.61 2.57 (1.66-3.07) <0.001
0.002 0.58 1.53 (1.08-2.15) 0.017
<0.001 0.63 1.74 (1.30-2.33) <0.001
0.027 0.62 1.06 (0.91-1.23) 0.7
0.557 0.51 1.02 (0.98- 1.06) 0.365
0.69
0.71
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associated with adverse characteristics in PC were also
identified in our study. The miRNAs, miR-449b and
miR-10b were seen previously by Fendler et al. [22],
differentiating between early or late recurrence. Fur-
thermore, several miRNAs (miR-126, miR-125-5p, miR-
10a/b) overlapped with the miRNAs identified by Prueitt
et al. [20] being associated with perineural invasion.
Finally, miR-449b and miR-484 overlapped with the
miRNAs associated with extraprostatic disease exten-
sion identified by Ambs et al. [16]. Among the down
regulated microRNAs found in this study, miR-154 was
also seen down regulated in patients with biochemical
recurrence after prostatectomy by Tong et al. [19]. In
addition to the microRNAs previously linked to aggressive
traits in PC several new microRNAs were identified to be
associated with recurrent disease.
The use of biochemical recurrence as surrogate end-
point of aggressive prostate cancer has limitations. Other
end-points like time to metastasis or progression to
death are stronger end-points for the clinical aggressive-
ness of prostate cancer, unfortunately this data was not
available for the cohort. The Gleason grade included in
the multivariate model of the validation cohort is based
on the original pathology grading. Gleason grading has
changed over time and a re-evaluation of the prostatec-
tomy specimens would strengthen the model.
The miR-449b gene is situated on chromosome 5 in
the second intron of the CDC20B gene. MiR-449b
shares seed sequence with miR-449a which is also tran-
scribed in the second intron of CDC20B. This off course
implies similar mRNA targets and thus similar functions.
In our study we found that miR-449a had a similar fold
change difference of 3.8 compared with 3.2 for miR-
449b between the recurrent and non-recurrent cases,
but miR-449a expression was not significantly associated
with recurrence in Mann–Whitney test. This difference
can be due to specificity and/or sensitivity of the PCR
probes for miR-449a and miR-449b respectively.
As described above the miR-449 cluster has previously
been associated with adverse outcomes in PC. In con-
trast to this miR-449 functional studies have provided
conflicting results. The miR-449 cluster has been impli-
cated in different cellular functions primarily in cell cycle
control and in cellular differentiation [27]. MiR-449b
has been shown to inhibit androgen receptor expres-
sion resulting in inhibited androgen mediated prolifera-
tion [28]. Studies using the Saos-2 osteosarcoma cell
line show that mir-449 cluster transcription is inducible
by the E2F1 transcription factor. Induced miR-449 has
been shown to cause causes cell cycle arrest and pro-
mote apoptosis by inhibiting CDK6 and CDC25A. In
this way it functions as a negative feedback mechanism
against E2F1 induced cell proliferation [28]. In otherstudies using cell lines originating from prostate, breast
and lung cancer the miR-449 cluster has also been
associated with cell cycle arrest and a role as tumor
suppressor although through different mechanisms
[29-31]. However a different functional role of miR-449
cluster is the interaction with LEF-1 a known effector
of the WNT pathway [32]. In the cell line hBM-MSC
the miR-449 cluster has been shown to directly inhibit
the LEF-1 gene and thus the WNT pathway. Although
WNT pathway inhibition in general inhibits cancer
growth, including PC, [33-35] other effects have been
observed that relate to PC progression. Firstly LEF-1
inhibition has been shown to inhibit osteoblast differ-
entiation and result in reduced bone density, a pheno-
type that would facilitate the establishment of PC cells
in bone [36]. Secondly studies looking at the interaction
between WNT signaling and androgen receptor func-
tion reveals a complex interaction with some evidence
that WNT pathway signaling enhances androgen recep-
tor signaling other evidence inhibiting androgen signal-
ing [37]. The miR-449 cluster has also been identified
targeting the NOTCH pathway thus altering cell differ-
entiation [38]. Whereas NOTCH pathway signaling
again in general is shown to induce EMT and cancer
progression, NOTCH signaling is also linked to inhibit-
ing bone formation. In this manner and like the inhib-
ition of LEF-1, the mechanism of action for miR-449b
overexpression in aggressive PC could be an increased
propensity to metastasize to bone. Further studies are
needed to investigate the functional role of miR-449 in
normal and malignant prostate cells.
Conclusion
The current study identified 31 miRNAs to be associated
with biochemical recurrence of prostate cancer after rad-
ical prostatectomy. The highest ranked miRNA, miR-
449b, was further validated in an independent cohort of
patients and shown to be an independent predictor of
recurrence after radical prostatectomy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MMM, KDS, TFO, LD, MB designed the study; MB and MMM provide tumor
tissue and clinical data; SH evaluated and graded the tumors; MMM and SH
performed the laboratory research; MMM and LD analyzed data; MMM, MB
and LD wrote the paper. All authors read and approved the final manuscript.
Acknowledgements
The project has been supported by a donation from the heritance of
manufacturer Holger K. Christiansen and by funding from the University of
Aarhus. The work was also supported by the John and Birthe Meyer
Foundation, The Danish Cancer Society, The Danish Strategic Research
Council and the Danish Advanced Technology Foundation. We thank Ms.
Pamela Celis, Ms. Margaret Gellett, Ms. Birgitte Trolle and Ms. Hanne Steen
for excellent technical assistance.
Mortensen et al. BMC Cancer 2014, 14:859 Page 7 of 7
http://www.biomedcentral.com/1471-2407/14/859Author details
1Department of Molecular Medicine, Aarhus University Hospital,
Brendstrupgaardsvej 100, 8200 Aarhus N, Denmark. 2Department of Urology,
Aarhus University Hospital, Brendstrupgaardsvej 100, 8200 Aarhus N,
Denmark. 3Department of Pathology, Aarhus University Hospital,
Nørrebrogade 44, 8000 Aarhus C, Denmark.
Received: 13 March 2014 Accepted: 30 October 2014
Published: 21 November 2014
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2008,
2010(127):2893–2917.
2. Gosselaar C, Roobol MJ, Schroder FH: Prevalence and characteristics of
screen-detected prostate carcinomas at low prostate-specific antigen
levels: aggressive or insignificant? BJU Int 2005, 95:231–237.
3. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V,
Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A,
Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T,
Blijenberg BG, Moss SM, de Koning HJ, Auvinen A, ERSPC Investigators:
Screening and prostate-cancer mortality in a randomized European
study. N Engl J Med 2009, 360:1320–1328.
4. Vickers A, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A,
Palmgren J, Garmo H, Holmberg L: Individualized estimation of the
benefit of radical prostatectomy from the Scandinavian Prostate Cancer
Group randomized trial. Eur Urol 2012, 62:204–209.
5. Klotz L: Active surveillance for prostate cancer: overview and update.
Curr Treat Options Oncol 2013, 14:97–108.
6. Ahmed FE: Role of miRNA in carcinogenesis and biomarker selection: a
methodological view. Expert Rev Mol Diagn 2007, 7:569–603.
7. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57–70.
8. Hammond SM: MicroRNAs as oncogenes. Curr Opin Genet Dev 2006, 16:4–9.
9. Kent OA, Mendell JT: A small piece in the cancer puzzle: microRNAs as
tumor suppressors and oncogenes. Oncogene 2006, 25:6188–6196.
10. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM: MicroRNA expression
and function in cancer. Trends Mol Med 2006, 12:580–587.
11. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li
Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang
J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang
CY: Characterization of microRNAs in serum: a novel class of biomarkers
for diagnosis of cancer and other diseases. Cell Res 2008, 18:997–1006.
12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan
EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher
CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin
DB, Tewari M: Circulating microRNAs as stable blood-based markers for
cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513–10518.
13. Bryant RJ1, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich
C, Visakorpi T, Hamdy FC: Changes in circulating microRNA levels
associated with prostate cancer. Br J Cancer 2012, 106:768–774.
14. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, Beissbarth T,
Kuner R, Sültmann H: Circulating miRNAs are correlated with tumor
progression in prostate cancer. Int J Cancer 2011, 128:608–616.
15. Ozen M, Creighton CJ, Ozdemir M, Ittmann M: Widespread deregulation of
microRNA expression in human prostate cancer. Oncogene 2008,
27:1788–1793.
16. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu
CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM: Genomic
profiling of microRNA and messenger RNA reveals deregulated
microRNA expression in prostate cancer. Cancer Res 2008, 68:6162–6170.
17. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T:
MicroRNA expression profiling in prostate cancer. Cancer Res 2007,
67:6130–6135.
18. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K,
Lein M, Kristiansen G, Jung K: Diagnostic and prognostic implications of
microRNA profiling in prostate carcinoma. Int J Cancer 2010, 126:1166–1176.
19. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han
J, Nemunaitis J: MicroRNA profile analysis of human prostate cancers.
Cancer Gene Ther 2009, 16:206–216.
20. Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM, Yfantis HG, Lee DH,
Stephens RM, Liu CG, Calin GA, Croce CM, Ambs S: Expression ofmicroRNAs and protein-coding genes associated with perineural
invasion in prostate cancer. Prostate 2008, 68:1152–1164.
21. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rüdiger T, Ströbel P, Riedmiller H,
Kneitz B: Expression of microRNA-221 is progressively reduced in
aggressive prostate cancer and metastasis and predicts clinical
recurrence. Int J Cancer 2010, 127:394–403.
22. Fendler A, Jung M, Stephan C, Honey RJ, Stewart RJ, Pace KT, Erbersdobler
A, Samaan S, Jung K, Yousef GM: miRNAs can predict prostate cancer
biochemical relapse and are involved in tumor progression. Int J Oncol
2011, 39:1183–1192.
23. Coppola V, De MR, Bonci D: MicroRNAs and prostate cancer. Endocr Relat
Cancer 2010, 17:F1–F17.
24. Heebøll S, Borre M, Ottosen PD, Andersen CL, Mansilla F, Dyrskjøt L, Orntoft
TF, Tørring N: SMARCC1 expression is upregulated in prostate cancer and
positively correlated with tumour recurrence and dedifferentiation.
Histol Histopathol 2008, 23:1069–1076.
25. Haldrup C, Mundbjerg K, Vestergaard EM, Lamy P, Wild P, Schulz WA, Arsov
C, Visakorpi T, Borre M, Høyer S, Orntoft TF, Sørensen KD: DNA methylation
signatures for prediction of biochemical recurrence after radical
prostatectomy of clinically localized prostate cancer. J Clin Oncol 2013,
31:3250–3258.
26. Chen Y, Gelfond JA, McManus LM, Shireman PK: Reproducibility of
quantitative RT-PCR array in miRNA expression profiling and comparison
with microarray analysis. BMC Genomics 2009, 10:407.
27. Yang X, Feng M, Jiang X, Wu Z, Li Z, Aau M, Yu Q: miR-449a and miR-449b
are direct transcriptional targets of E2F1 and negatively regulate
pRb-E2F1 activity through a feedback loop by targeting CDK6 and
CDC25A. Genes Dev 2009, 23:2388–2393.
28. Lize M, Pilarski S, Dobbelstein M: E2F1-inducible microRNA 449a/b
suppresses cell proliferation and promotes apoptosis. Cell Death Differ
2010, 17:452–458.
29. Noonan EJ1, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C,
Dahiya R: miR-449a targets HDAC-1 and induces growth arrest in
prostate cancer. Oncogene 2009, 28:1714–1724.
30. Noonan EJ, Place RF, Basak S, Pookot D, Li LC: miR-449a causes Rb-
dependent cell cycle arrest and senescence in prostate cancer cells.
Oncotarget 2010, 1:349–358.
31. Ren XS, Yin MH, Zhang X, Wang Z, Feng SP, Wang GX, Luo YJ, Liang PZ,
Yang XQ, He JX, Zhang BL: Tumor-suppressive microRNA-449a induces
growth arrest and senescence by targeting E2F3 in human lung cancer
cells. Cancer Lett 2013, 344:195–203.
32. Paik S, Jung HS, Lee S, Yoon DS, Park MS, Lee JW: miR-449a regulates the
chondrogenesis of human mesenchymal stem cells through direct
targeting of lymphoid enhancer-binding factor-1. Stem Cells Dev 2012,
21:3298–3308.
33. Chesire DR, Ewing CM, Gage WR, Isaacs WB: In vitro evidence for complex
modes of nuclear beta-catenin signaling during prostate growth and
tumorigenesis. Oncogene 2002, 21:2679–2694.
34. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB: Detection and
analysis of beta-catenin mutations in prostate cancer. Prostate 2000,
45:223–234.
35. Polakis P: Wnt signaling in cancer. Cold Spring Harb Perspect Biol 2012,
4:a008052.
36. Noh T, Gabet Y, Cogan J, Shi Y, Tank A, Sasaki T, Criswell B, Dixon A, Lee C,
Tam J, Kohler T, Segev E, Kockeritz L, Woodgett J, Müller R, Chai Y, Smith E,
Bab I, Frenkel B: Lef1 haploinsufficient mice display a low turnover and
low bone mass phenotype in a gender- and age-specific manner.
PLoS One 2009, 4:e5438.
37. Terry S, Yang X, Chen MW, Vacherot F, Buttyan R: Multifaceted interaction
between the androgen and Wnt signaling pathways and the implication
for prostate cancer. J Cell Biochem 2006, 99:402–410.
38. Marcet B, Chevalier B, Luxardi G, Coraux C, Zaragosi LE, Cibois M, Robbe-
Sermesant K, Jolly T, Cardinaud B, Moreilhon C, Giovannini-Chami L, Nawrocki-
Raby B, Birembaut P, Waldmann R, Kodjabachian L, Barbry P:
Control of vertebrate multiciliogenesis by miR-449 through direct repression
of the Delta/Notch pathway. Nat Cell Biol 2011, 13:693–699.
doi:10.1186/1471-2407-14-859
Cite this article as: Mortensen et al.: High miR-449b expression in
prostate cancer is associated with biochemical recurrence after
radical prostatectomy. BMC Cancer 2014 14:859.
